Avecho restarts final Phase III insomnia trial recruitment after positive interim review

Recruitment Resumes After Key Interim Milestone

Avecho Biotechnology (ASX:AVE) has reignited enrolment in the final stage of its pivotal Phase III clinical trial testing its TPM®-enhanced cannabidiol (CBD) soft-gel capsule for insomnia treatment. This move follows a positive interim analysis conducted on 244 participants, which saw the independent Data Monitoring Board (DMB) unanimously recommend continuing the trial at its originally planned size of 519 participants, rather than increasing the cohort.

The DMB’s decision is notable. Typically, a trial might expand its sample size if interim results suggest weaker or more variable treatment effects than anticipated. That the DMB did not call for more participants suggests the study is progressing in line with its original assumptions, even though Avecho remains blinded to efficacy data.

Trial Design and Safety Profile

The multi-centre, randomized, double-blind, placebo-controlled trial evaluates two dosages of the CBD TPM® capsule (75mg and 150mg) against placebo over an eight-week treatment period. Participants track sleep quality and insomnia severity through validated questionnaires and sleep diaries.

Safety data from the interim analysis showed no serious adverse events among the 244 participants assessed, a reassuring signal as the trial scales up. Avecho’s CEO Dr Paul Gavin described the interim analysis as “the single biggest risk to the study,” now behind them, enabling confident progression to the final cohort recruitment phase.

Accelerating Enrolment and Market Implications

Recruitment has restarted at existing clinical sites, with additional sites to be progressively activated to speed up enrolment. Avecho expects to complete recruitment of the remaining approximately 320 participants within roughly 12 months.

The trial is designed to meet regulatory requirements of the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration, and the European Medicines Agency. A successful Phase III outcome would underpin Avecho’s application for pharmaceutical registration of its CBD TPM® capsule for insomnia management.

Regulatory changes in Australia since 2020 allow for over-the-counter sales of approved CBD products without prescription, presenting a significant commercial opportunity. Avecho aims to be the first to market with a Phase III-backed CBD insomnia treatment, targeting a market projected to exceed US$125 million annually in Australia alone.

Insomnia’s Market and Societal Impact

Insomnia affects between 10-30% of the global population, with chronic cases impacting 10-15%. The disorder carries considerable social and economic costs, including daytime sleepiness, impaired memory, and reduced work productivity. In Australia, up to 60% of people experience some insomnia symptoms, with an estimated economic burden of A$19.1 billion.

Avecho’s trial stands out as the largest Phase III study of cannabidiol for insomnia, a field where no prior Australian Phase III CBD trials have succeeded. The company’s progress is therefore closely watched by investors and the wider healthcare sector.